<SEC-DOCUMENT>0001070081-24-000029.txt : 20241202
<SEC-HEADER>0001070081-24-000029.hdr.sgml : 20241202
<ACCEPTANCE-DATETIME>20241202071510
ACCESSION NUMBER:		0001070081-24-000029
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20241127
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241202
DATE AS OF CHANGE:		20241202

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35969
		FILM NUMBER:		241517402

	BUSINESS ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		500 WARREN CORPORATE CENTER DRIVE
		CITY:			WARREN
		STATE:			NJ
		ZIP:			07059

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tmb-20241127x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.8.0.95 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 12/1/2024 6:20:53 PM -->
<!-- iXBRL Library version: 1.0.9027.2259 -->
<!-- iXBRL Service Job ID: dd337c36-4832-452c-9867-f9c430c93340 -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ptct="http://www.ptcbio.com/20241127" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityCentralIndexKey" id="Tc_Kny3NXcbFES9jY3A4LBEDg_2_1">0001070081</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:AmendmentFlag" id="Tc_W7Vshdy70UmEuivjp3k60g_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="tmb-20241127.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001070081</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-27</xbrli:startDate><xbrli:endDate>2024-11-27</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_96648a38_c0f7_4684_b696_b5d7445d59a6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:DocumentType" id="Narr_bLsj63tgK0OUDo06i7jgLQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Date of Report (Date of earliest event reported): </span><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_ojaMruoDVkeM-HseBB0_Ww"><b style="font-size:9pt;font-weight:bold;">November&#160;27, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityRegistrantName" id="Narr_L83Du03NWkG9t_03uHFNPg"><b style="font-weight:bold;">PTC THERAPEUTICS, INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact Name of Company as Specified in Charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_55447ebd_8ac3_48f2_9214_a2803b87ebd3"></a><a id="Tc_WBEY1QsJG0qMV-bWeTkUPQ_2_0"></a><a id="Tc_dyMVT3qIPkeOahWYsxnkcw_2_2"></a><a id="Tc_x8KsSh7Z_0Kz5dSWV41rfQ_2_4"></a><a id="Tc_5OZWbJ8EWUGD6kelK_lk6A_3_0"></a><a id="Tc_douUvQ82_USLGBCGSZU5xg_3_2"></a><a id="Tc_rF9rDO6vR0e-63rJnhvxHw_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_eJjXzFK03keuopRPMANf5Q_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityFileNumber" id="Tc_SfD8PALNZUGB-KScF4Q01A_1_2"><b style="font-size:9pt;font-weight:bold;">001-35969</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityTaxIdentificationNumber" id="Tc_DdcXfBP45kuYrcH0A1gkQQ_1_4"><b style="font-size:9pt;font-weight:bold;">04-3416587</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or Other Jurisdiction</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Commission</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(IRS Employer</p></td></tr><tr><td style="vertical-align:bottom;width:31.75%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">of Incorporation)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">File Number)</p></td><td style="vertical-align:bottom;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.76%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_c0dd52bc_18a5_4ddb_b41a_c697e874a0ff"></a><a id="Tc_IVQNZdZxOUeM4gtw_GGgyQ_2_0"></a><a id="Tc_XyU65D6wY0uMNqJL_-veiw_3_0"></a><a id="Tc_p-Bh9c_3yUasEUmKa-yR1g_3_3"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:82.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityAddressAddressLine1" id="Tc_HTo0rO1LnUKD7-vZEy5QzA_1_0"><b style="font-size:9pt;font-weight:bold;">500 Warren Corporate Center Drive</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityAddressCityOrTown" id="Narr_zDcVq8wmSkWr-mUCU3jx8Q"><b style="font-size:9pt;font-weight:bold;">Warren</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityAddressStateOrProvince" id="Narr_jXOixc14Ekq-1GfIN8QmrA"><b style="font-size:9pt;font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:EntityAddressPostalZipCode" id="Tc_Ll-ydGgm_021sgPkoJdWKQ_2_3"><b style="font-size:9pt;font-weight:bold;">07059</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of Principal Executive Offices)</p></td><td style="vertical-align:top;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.13%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Registrant&#8217;s telephone number, including area code: </span><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:CityAreaCode" id="Narr_4vITLWlpNEmoGNW-KuuSjg"><b style="font-size:9pt;font-weight:bold;">908</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:LocalPhoneNumber" id="Narr_NVf5i4P11UusXEndMIx8tw"><b style="font-size:9pt;font-weight:bold;">222-7000</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Not applicable</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former Name or Former Address, if Changed Since Last Report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:36pt;margin:0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_yPEfOoj3BEW9chCShzV3cw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_NxYJmQ5jekGrT6LMVzRsbQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_KrWwJjTLeE-NcU0dKU2neA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:21.6pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_gSIkmnKoOEm0KSD-fct3Ww"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_78f9e492_9551_4dcc_bd52_e93e8cab4c26"></a><a id="Tc_1FgKU976OEqdmJt47pCtXw_1_0"></a><a id="Tc_yNwhNY28qkG7JdBrZtPIHw_1_2"></a><a id="Tc_mepGR7zrIkC-sj0RQQgEUA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:37.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:37.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:37.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:37.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:Security12bTitle" id="Tc_fhm4NPmuHkmCBPHYqWfkNg_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:19.99%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" name="dei:TradingSymbol" id="Tc_th9KmC7r10C35sAYmKYYOQ_2_2"><span style="font-size:9pt;">PTCT</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:37.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_RI2JeI5-6kCsTi21Qdh0yg_2_4"><span style="font-size:9pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_hznf45cJHEOdeSdAiodnZQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_b3891bd9_2b5c_4007_8beb_ab1bff61963a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;1.01.&#160;Entry Into a Material Definitive Agreement.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="white-space:pre-wrap;">On November 27, 2024, PTC Therapeutics, Inc. (the &#8220;Company&#8221;), PTC Therapeutics HD, Inc. and Novartis Pharmaceuticals Corporation (&#8220;Novartis&#8221;) entered into a License and Collaboration Agreement (the &#8220;Agreement&#8221;), relating to the Company&#8217;s PTC518 Huntington's disease program which includes related molecules.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Under the Agreement, the Company will receive an upfront payment of $1.0 billion on the Effective Date and up to $1.9 billion in development, regulatory and sales milestones, a 40% share of U.S. profits and losses, and tiered double-digit royalties on ex-U.S. sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Pursuant to the Agreement, the Company will continue to conduct the ongoing Phase 2A Clinical Trial and the ongoing OLE Clinical Trial pursuant to its existing development plan, with the goal of transitioning the ongoing OLE Clinical Trial to Novartis within 12 months after the Effective Date (as defined below). Novartis will be responsible for all other development of licensed compounds and licensed products and the manufacture and commercialization of licensed compounds and licensed products worldwide.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The Agreement will be effective on the date (the &#8220;Effective Date&#8221;) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has occurred and other customary conditions are met. The parties anticipate that the Effective Date will be in the first quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The Agreement will commence on the Effective Date and, unless earlier terminated in accordance therewith, shall continue in force and effect until (a) with respect to the royalty territory, on a licensed product-by-licensed product and country-by-country basis, the royalty term end date for such licensed product in such country and (b) with respect to the profit-sharing territory, on a licensed product-by-licensed product basis, until the exploitation of such licensed product has completely terminated. Either party may terminate for material breach of the Agreement. Novartis may terminate for convenience or for safety or regulatory issue. The Company may also terminate (a) solely with respect to such country or other jurisdiction, (b) in the case that such country or other jurisdiction is United States, Brazil, Switzerland, Russia, United Kingdom, France, Germany, Italy and Spain (a &#8220;Major Market&#8221;), solely with respect to all Major Markets, or (c) in its entirety, for material breach of diligence obligations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, which will be filed as an exhibit to the Company&#8217;s annual report on Form 10-K for the fiscal year ending December&#160;31, 2024.</p><a id="_ef00b37e_0b0d_46b9_95e8_1011d7b7e5f4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Item&#160;7.01.&#160;Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On December&#160;2, 2024, the Company issued a press release in which it announced the signing of the Agreement. The Company will hold a conference call at 8:30 am EST on December 2, 2024 to discuss this news. Directions on how to access the conference call are included in the press release, which is attached to this Current Report on Form 8-K (this &#8220;Report&#8221;) as Exhibit 99.1 and is incorporated by reference into this Item 7.01.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The information set forth in or incorporated by reference into this Item 7.01, including Exhibit 99.1, shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.01.&#160;Financial Statements and Exhibits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(d)&#160;Exhibits</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:bottom;width:2.06%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:82.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="tmb-20241127xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated December&#160;2, 2024 issued by PTC Therapeutics, Inc.</span></a></p></td></tr><tr><td style="vertical-align:bottom;width:15%;margin:0pt;padding:0pt 3pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:82.93%;margin:0pt;padding:0pt 2pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The cover page from this Current Report on Form 8-K, formatted in Inline XBRL</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b52b64ca_034c_4f82_b098_3b8fe20aff81"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cautionary Statement Concerning Forward Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Report contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this Report, other than statements of historical fact, are forward-looking statements, </p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">including statements <span style="background:#ffffff;">with respect to the future expectations, plans and prospects for the Company, including with respect to the Company&#8217;s right to receive any upfront payment from Novartis; the Company&#8217;s right to receive </span>development, regulatory and sales<span style="background:#ffffff;"> milestones, profit sharing and royalty payments from Novartis; the continued development of </span>PTC518<span style="background:#ffffff;">; PTC expected use of proceeds from the transaction; future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, "guidance", "plan," "anticipate," "believe," "estimate," "expect," "intend," "may," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for the Company's products or product candidates that the Company commercializes or may commercialize in the future; the expected benefits and opportunities related to the licensing agreement may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in development; success in early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; data for PTC518 may not be sufficient for obtaining regulatory approval; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of the Company's products and product candidates; the Company's scientific approach and general development progress; and the factors discussed in the &#8220;Risk Factors&#8221; section of the Company&#8217;s most recent Quarterly Report on Form&#160;10-Q and Annual Report on Form&#160;<span style="white-space:pre-wrap;">10-K as well as any updates to these risk factors filed from time to time in the Company&#8217;s other filings with the Securities and Exchange Commission.  You are urged to carefully consider all such factors.&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="white-space:pre-wrap;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product candidate or product candidate or product will receive or maintain regulatory approval in any territory, or prove to be commercially successful.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">The forward-looking statements contained herein represent the Company&#8217;s views only as of the date of this Report and the Company does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this Report except as required by law. </p><a id="_e8cf83be_f354_496a_84d0_eb6891fd4fb5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Signature</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PTC Therapeutics,&#160;Inc.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: December&#160;2, 2024</p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:44.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Pierre Gravier</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:44.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20241127xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 12/1/2024 06:20:47 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:0.75pt;margin-right:9pt;width:84.3pt;z-index:251659264;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;width:84.3pt;"><img src="tmb-20241127xex99d1002.jpg" alt="Graphic" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington&#8217;s Disease Program</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- PTC to receive $1.0B in cash at closing -</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -</i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt 0pt 0pt 18pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- </i></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">WARREN, N.J., Dec. 2, 2024</b><font style="font-family:'Arial','Helvetica','sans-serif';"> - PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington&#39;s disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of </font><a name="_Int_6SNK5Oyz"></a><font style="font-family:'Arial','Helvetica','sans-serif';">$1.0 billion</font><font style="font-family:'Arial','Helvetica','sans-serif';">, up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">&quot;PTC518 is the leading oral disease-modifying therapy in development for Huntington&#39;s disease and the economics of this agreement are consistent with the promise of this treatment,&quot; said Matthew B. Klein, M.D., Chief Executive Officer, PTC Therapeutics. &quot;This collaboration combines PTC&#8217;s expertise in developing small molecule splicing therapies with Novartis&#8217;s expertise in global development and commercialization of neuroscience therapies. We are excited to collaborate with Novartis to accelerate the potential of PTC518 for the hundreds of thousands of HD patients worldwide in need of a therapy designed to be well-tolerated and an effective disease-modifying therapy. PTC will use the proceeds of this transaction to expand our splicing platform as well as to support commercial and development portfolio activities.&quot;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">&#8220;Huntington&#8217;s Disease is a devastating, fatal, familial disease. This agreement with PTC is intended to bolster our neuroscience pipeline and reflects our strategic focus and commitment to explore new and potentially transformative approaches for neurodegenerative diseases with high unmet needs,&#8221; said</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> Vas Narasimhan, CEO of Novartis.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> &#8220;We look forward to building on our expertise in neurodegenerative diseases and experience in HD with the intention to advance this potential first in class oral therapy for the HD community.&#8221;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">PTC518 was discovered from PTC&#39;s validated splicing platform and is currently being studied in the ongoing Phase 2 PIVOT-HD trial. Interim results reported in June 2024 demonstrated that PTC518 treatment resulted in durable, dose-dependent reduction in blood and cerebrospinal fluid (CSF) mutant Huntingtin protein (HTT) levels as well as early signals of dose-dependent benefit on key clinical measurements at 12 months.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">1</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:0.75pt;margin-right:9pt;width:84.3pt;z-index:251658240;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;width:84.3pt;"><img src="tmb-20241127xex99d1002.jpg" alt="Graphic" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">Importantly, PTC518 continues to demonstrate a favorable safety and tolerability profile.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">1</sup><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;white-space:pre-wrap;">Novartis will assume responsibility for PTC518&#8217;s development, manufacturing and commercialization, following the completion of the on-going placebo-controlled portion of PIVOT-HD, which is expected to occur in H1 2025.  </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">The companies will share U.S. profits and losses, on a 40/60 basis (40% PTC and 60% Novartis).</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">The closing of the transaction is subject to customary closing conditions, including regulatory clearance. The parties anticipate that the agreement will close in the first quarter of 2025.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Conference Call and Webcast Details:</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">PTC will hold a conference call at 8:30 am EST today to discuss this news. To access the call by phone, please </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">click</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> here to register and you will be provided with dial-in details. To avoid delays, we recommend participants dial in to the conference call 15 minutes prior to the start of the call. The webcast conference call can be accessed on the Investor section of the PTC website at </font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">https://ir.ptcbio.com/events-presentations</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">. </font><a name="_Int_nNsXCwzB"></a><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">A replay of the call will be available approximately two hours after completion of the call and will be archived on the company&#39;s website for </font><a name="_Int_f42xfxZ5"></a><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">30 days</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"> following the call.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Huntington&#39;s Disease</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Huntington&#39;s disease (HD) is a fatal, hereditary, genetic disorder of the central nervous system.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">2 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">It is caused by a defective gene. This gene produces a protein, called Huntingtin, which is involved in the functioning of the nerve cells in the brain (neurons). When the gene is defective, it produces an abnormal (or mutated) Huntingtin protein that is toxic and causes neuron damage and neuron death.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">3 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">HD usually presents in people who are in their 30s or 40s. Symptoms can present earlier in life, and this is called the Juvenile HD.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">3,4 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">There are also cases of infantile HD, when symptoms develop in children who are younger than 10 years old.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">3 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">While symptoms vary from person to person, the disease primarily affects the brain and results in abnormal movements, difficulties with speech, swallowing and walking, as well as a number of other symptoms including behavioral, cognitive and motor symptoms.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">5,6 </sup><font style="font-family:'Arial','Helvetica','sans-serif';">While there are therapies approved for specific disease symptoms, currently, there is no cure for HD and there are no approved drugs that delay the onset or slow disease progression.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About PTC&#39;s Splicing Platform </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">PTC has pioneered the use of advanced alternative splicing technology to identify small molecules that affect mRNA splicing for the treatment of disease of high unmet need. PTC&#8217;s validated splicing platform identified the first-ever approved small molecule splicing modifier - Evrysdi</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:9pt;vertical-align:top;">&#174; </sup><font style="font-family:'Arial','Helvetica','sans-serif';">(risdiplam), and PTC has leveraged the extensive learnings from the SMA program to broaden the platform to support discovery programs across numerous therapeutic areas including neurodegenerative disease, oncology and </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:0.75pt;margin-right:9pt;width:84.3pt;z-index:251658240;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;width:84.3pt;"><img src="tmb-20241127xex99d1002.jpg" alt="Graphic" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">metabolism. PTC has also developed a powerful high-throughput drug discovery platform (PTSeek&#8482;) that identifies small molecules that modulate pre-mRNA splicing to upregulate or down regulate targeted protein production, accelerating the discovery and early preclinical development process for candidate small molecule splicing agents. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;background:#ffffff;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;">About PTC Therapeutics, Inc.</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC&#39;s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC&#39;s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC&#39;s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at&#160;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">www.ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">&#160;and follow us on Facebook, Instagram, </font><a name="_Int_MHkBFzlE"></a><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;">LinkedIn</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;background:#ffffff;"> and X.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">For More Information:</b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Investors:</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">Ellen Cavaleri</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">+1 (615) 618-6228</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">ecavaleri@ptcbio.com</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Media:</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">Jeanine Clemente</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">+1 (908) 912-9406</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">jclemente@ptcbio.com</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">&#160;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;background:#ffffff;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Forward-Looking Statement: </b></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historic fact, are forward-looking statements, including statements with respect to the future expectations, plans and prospects for PTC, including with respect to PTC&#8217;s right to receive any upfront payment from Novartis; PTC&#8217;s right to receive development, regulatory and sales milestones, profit sharing and royalty payments from Novartis; the continued development of PTC518; future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words, </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:0.75pt;margin-right:9pt;width:84.3pt;z-index:251658240;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;width:84.3pt;"><img src="tmb-20241127xex99d1002.jpg" alt="Graphic" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">&quot;guidance&quot;, &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;expect,&quot; &quot;intend,&quot; &quot;may,&quot; &quot;target,&quot; &quot;potential,&quot; &quot;will,&quot; &quot;would,&quot; &quot;could,&quot; &quot;should,&quot; &quot;continue,&quot; and similar expressions.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">PTC&#39;s actual results, performance or achievements could differ materially from those expressed or implied by forward -looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for PTC&#39;s products or product candidates that PTC commercializes or may commercialize in the future; the expected benefits and opportunities related to the licensing agreement may not be realized or may take longer to realize than expected due to a variety of reasons, including any inability of the parties to perform their commitments and obligations under the agreement, challenges and uncertainties inherent in development; success in early clinical trials, especially if based on a small patient sample, does not ensure that later clinical trials will be successful, and early results from a clinical trial do not necessarily predict final results; data for PTC518 may not be sufficient for obtaining regulatory approval; significant business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of PTC&#39;s products and product candidates; PTC&#39;s scientific approach and general development progress; and the factors discussed in the &quot;Risk Factors&quot; section of PTC&#39;s most recent Annual Report on Form 10-K, as well as any updates to these risk factors filed from time to time in PTC&#39;s other filings with the SEC. You are urged to carefully consider all such factors.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful. </font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;">The forward-looking statements contained herein represent PTC&#39;s views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.28;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">References:</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;background:#ffffff;"> </b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;">PTC Therapeutics,</i><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;"> </font><i style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;">&#8220;Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington&#39;s Disease Patients,&#8221; news release, June 20, 2024, </i><i style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:italic;font-weight:normal;">https://ir.ptcbio.com/news-releases/news-release-details/interim-pivot-hd-results-demonstrate-evidence-favorable-cns</i></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><div style="clear:both;"></div><div style="clear:left;float:left;height:51.35pt;margin-left:0.75pt;margin-right:9pt;width:84.3pt;z-index:251658240;"><div style="height:51.35pt;left:0pt;padding-bottom:0pt;position:relative;width:84.3pt;"><img src="tmb-20241127xex99d1002.jpg" alt="Graphic" style="height:51.35pt;width:84.3pt;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">World Health Organization, 2020. 8A01.10 Huntington disease. Available at: https://icd.who.int/browse11/l-m/en#/http://id.who.int/icd/entity/2132180242&#160;Accessed&#160;October 2021.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Gatto EM, Gonz&#225;lez Rojas N, Persi G, et al. Clin Parkinsonism Rel Disord 2020;3:100056.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Tabrizi SJ, Flower MD,&#160;Ross CA, et al. Nat Rev Neurol 2020;16(10):529&#8211;546.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Roos RAC. Orphanet J Rare Dis 2010;5:40.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Aptos';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-style:normal;font-weight:normal;">Kirkwood SC, Su JL, Conneally P, et al. Arch Neurol 2001;58(2):273&#8211;278.</font></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Aptos';font-size:11pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20241127xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20241127xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !G *D# 2(  A$! Q$!_\0
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M[3Y#F6V6X/\ TW)D'Y-FLVY_97W_ -,UBH?:?W?TB"[\7Z+8DB;4[9&'\/F
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M*?B)I_Q6^'VB>*--D1H=0MUD=$.?*EQ\\9]U;(KJQZ=HOH!UM%%%>0 4444
M>8?M :>L_@Y+O;F2VF4@^@/!KYM-S[U]0?'698?AQJ!;N5 ^N:^2?M7O7Y;Q
M)!+&IKJE^I^P\)WJ8!I])/\ 0^G/V==<:_\ #E]8.VXVDP9<]E8=/S!KUNOG
MC]EVY9]3UN//RF)&/UR?\:^AZ^UR.HZF IM]+K[F?!<1451S.K&/6S^](***
M@O;R*PM9;B9MD4:EF)KW&TE=GSB3;LCR/]L#_DVOQY_UXC_T8E?C)7[@?%'P
M#/\ %SX3Z[X::\&F2ZS;A!.T>\0C<K#*Y&>!Z]Z^-?\ AU;>?]%"@_\ !8W_
M ,<KU,'7IP@^9VN.2Y6T?4'[&?\ R;%X _Z\7_\ 1TE>T5Q/P6^'3?"7X7>'
MO"+WPU)M*@,)NEC\L29=FSMR<?>]:[:N"HU*;:[DA11168'SQ^W]_P FJ^+_
M /KI9?\ I9#7Y%1_?7ZBOVV_:#^$K_'#X3ZQX-CU)=)?4&@87;1>:$\N9)/N
MY&<[,=>]?'R_\$KKQ6!_X6%!P?\ H&-_\<KUL)7ITX-2?4#[6^#?_))_"'_8
M*M__ $6*C^,7POT[XQ?#O5_"NIC;%>Q8BF R891RCCZ''X9'>MOP7X>/A/PE
MH^BM,+DZ?:1VQF"[=^Q0,X[9Q6U7F.5I<R _#'XJ?"OQ!\'O%]YX>\163VMU
M"Q\N0C]W.G9T/<&NW_9Y_:G\6?L]7\B:8R:CH=PP:XTJY)\MC_>4_P +>XK]
M8OBC\&_"/QDT0Z9XKT>'48AGRIB-LL)]4<<J?I7QGX\_X)<N;F2;P?XN"P$D
MK::K!DK[>8N.GN*]>&*IU8\M4#T'PU_P4S^'.HVZ'6=+U?2)MOS+'$)QGV((
MJMK_ /P4R\&(XM_#OAS5M:NY6$<*R!80S'@<<GKVKP#_ (=F_%;S,?VAX;V9
M^]]LESCZ>57M/[//_!/&X^'7CS3O$_B[6K+51I[>;#IUK"Q4RC[K,S'D \XQ
MU K*4,+%7O<#["\#ZAK&K>$],O=?LX=/U:YA$L]I Q982W(3)ZD @'WK=HZ4
M5Y;U \8_:AUM+'P;:V6[#W5P./9>:^6#="O2OVFO&BZWX\_LZ%]T&FIY9P>-
MYY/]*\>-U7Y+G5;ZQC9M;+3[O^"?T)PU@)8;+*:DM9>]]^WX6/J+]DZS9[?7
MKXCY6:.)3],D_P Q7T'7FG[/?AMO#OPTL#*NV>])NG!_VON_H!7I=?H>5470
MP5.#WM?[]3\:S_$+$YG6G':]ONT_0*X;Q;J?]L>,=%\+0G*MF^O<=HD^ZI_W
MF_E7;NP1&8G  R37BWP3U?\ X33XB>./$3'<B2K9P'L(P3C'UVY_&ML54]ZG
M07VW^"U?^7S,<OH7IUL6]J<?_)I.R^[?Y'J7C"\UK3_#5_<>'=/@U76HX\VM
MG<S>3'*V1PS_ ,(QFO ?A7^TOXZ\=>$/&OB?5/!6EZ9HWAVRO6$L&HF1Y;NW
M7=Y17:"%(!^;VKZ6/0U\=_ P?\8L?&K_ *[ZY_Z):O8II.+NNQXQZ9X;_:2O
M==USX-6#Z);Q+X]TVYOYW6=B;0Q1+(%48^8'.,G%4OA[\>?B+\2/'VN:=I7@
MC26\,Z-K,FEW>IOJA6951B"XC*\G SBO ?@GX#B\)_$_]F?4X]9UK4VUK1K^
MX>VU.\,\%H1:CY+="!Y:?-TYZ#TKH/V=M1\%Z)\:?'M]KGC^]T/6AXINX[70
M/[5\FTNPSL SP8^<YX!S73*G!)V5]/U8'?>-_P!KGQ9X5\9^.;:R\#66L>&_
M!\L8U&[74O)N/*? WJA4@D$]*ZW]HG]IP_!KP'X;UW2-'37+W7'WPV<TA3$"
MQ&21R5!^Z-OYFOE+XR^'M1O_ (C?&S58M2OXM%T_4K)M7TVU<*EW:%E\P-WR
M.,8KTS]I:/6?'_Q%\$>%O!&AP:\EIX2O;R&U>\6 1QW$1MBY9N"54J0O<T_9
M0O'3U^Y >U?'/X_:O\.8/A^GAC1++Q#>^+[U+*U2ZNC#&&=5*'< >"6'-<9J
MW[8^J:3\+O&.L77@Z.R\7>%=3M],O](EO-\#-*V%=)0HR",G&/3GFO'?%U_)
M\1_A+^RI%:WMSI-Q+J\&EB]@(,T$D++;F1<\9!C+#/M79_M-_!/1_@W^R_XK
M2UU"_P!4U'5]7L[O4M7U"4-/._G* 20,  $X^I]L*-.FN6,EK?\ 4#UY?C-\
M0- ^$/B/QKXL\':7I;6-FEY8VUIJ1G6X5@#\Y"Y7K5;P;^TIJ7BSQGX(T%=!
MMHCXC\,G73(+ALQ2;B!$..1QU-<!$WA;5/V5/&>@>#?&U]X\U$:0MS<0WFI_
M;IK8[5RB\#:HP<#VKD/V<M<L/%GQK^%/]CW<6H?V1X%-M?\ D-N^S2B0Y1_1
MN1Q4^SBXR=MO\@/9/A?\<_B;XV^*^M^$=5\"Z/IEMX?DA75[N#53(T*S1M)$
M47;\^0O..E:>B?M*M<_"[XB>,;_151?"FJWVG):V\V3<B @*Q8CY2V?PJI\%
MO^3F?V@?^NFB_P#I))7CNCV\MS^RW^T"D2-(_P#PE&LMM49. ZU/)%O;^7\0
M/8/A#^TGKOBGQ/J'A_QIX6@\/:BFE)K=HUA=&YCEMG7< 3@88#_]50_!W]HW
MQG\3O$UA)/\ #YK?P7JDMQ#::S97)G:W:(D?Z0-H"!L<=.?6F_!G]HG3?%^H
M67A+1=.76M-TGPU;7-UJMG+Y@$@B : KC&[(QC->5_!WXA:)H7QZT6U^'&IW
M#^'/%=Q=#5_"ET,R:7/&"3*%S\@8CI_]:G[-/F]VP'V[7)?%+QU;?#SP9?ZM
M.P\Q4*01D\O(>%'YUU4LJ01/)(P1$!9F8X 'K7P?^T;\9#\1_%9M-/D+:%IS
M%("O29^C2?T'M]:^;S/&+!T&U\3T7^?R/K.&\EGG.-4&OW<=9/R[>K_S9Y_?
MZQ-J5[/=W$ADGG<R.Y[L3DUT_P */"4WQ \<Z=I4:EH3()+A@/NQCEC_ $_&
MO.1<,S!5!))P !7V-\"O"4GP@\%VNNW^E37FJZU(B;(V16@C/*@[B.O4U\#E
MN!EC<0HO9:O^O,_;^(LQADV7RG'2<M(KS[_+<^A[:WCL[:*")0D<:A%4=@!@
M5+7GGPW^-&F?$R]^S6%A>6S+:BXD:X50$;=M,9P3\P^4^F&'->AU^JN+CHS^
M96VW=B$!@01D'J#56PTFRTI76RL[>S5SEA!$J;C[X'-6Z*FRO<:DTFD]&%9]
MMX>TJRLKBSM]-LX+.Y+&>WB@18Y=W#;E P<]\]:T**9)FQ>&M(@DL)(M*LHY
M+!#'9LEN@-LI&"L9Q\@(X(&*HM\/?"KWYOF\-:.;TR>:;DV$7F%\YW;MN<Y[
MUT%%.[ RY?"VBS&^,FD6$AO@!=EK9#]HQT\SCYOQS3[7P[I-E>)=V^F6<%TD
M/V=9XK=%=8O[@8#(7@<=*T:*+L#(C\(Z%%#90IHNGI%8R&:U1;6,+;R9R7C&
M/E;/.1@YJWJNC6&O636>IV-MJ-HQ!:"[B66,D'()5@15RBB[ Q](\':!X?\
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<B@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>tmb-20241127.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/1/2024 6:20:59 PM-->
<!--Modified on: 12/1/2024 6:20:59 PM-->
<xsd:schema targetNamespace="http://www.ptcbio.com/20241127" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ptct="http://www.ptcbio.com/20241127" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20241127_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20241127_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="tmb-20241127_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>tmb-20241127_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/1/2024 6:20:59 PM-->
<!--Modified on: 12/1/2024 6:20:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="tmb-20241127.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.ptcbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>tmb-20241127_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/1/2024 6:20:59 PM-->
<!--Modified on: 12/1/2024 6:20:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesTable" xlink:label="dei_EntityAddressesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesTable" xlink:to="dei_EntityAddressesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesLineItems" xlink:label="dei_EntityAddressesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesLineItems" xlink:to="dei_EntityAddressesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>tmb-20241127_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.8.0.95 -->
<!--Based on XBRL 2.1-->
<!--Created on: 12/1/2024 6:20:59 PM-->
<!--Modified on: 12/1/2024 6:20:59 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="tmb-20241127.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638686740592068793" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638686740592068793" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638686740592068793" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638686740592068793" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638686740592068793" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638686740592068793" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638686740592068793" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638686740592068793" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638686740592068793" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638686740592068793" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638686740592068793" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638686740592068793" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638686740592078776" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_WrittenCommunications_638686740592078776" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SolicitingMaterial_638686740592078776" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638686740592078776" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638686740592078776" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638686740592078776" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638686740592078776" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638686740592078776" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638686740592078776" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638686740592078776" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638686740592078776" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638686740592088769" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638686740592088769" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45849127415984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 27, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 27,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PTC THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3416587<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">500 Warren Corporate Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Warren<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">222-7000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PTCT<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M4$L! A0#%     @ Y#F"6:="K+ON    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ Y#F"69E<G",0!@  G"<
M !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #D.8)94:CB)%8$  "^$   &               @($-"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ Y#F"69^@&_"Q @  X@P
M  T              ( !F0P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #D
M.8)9EXJ[',     3 @  "P              @ %U#P  7W)E;',O+G)E;'-0
M2P$"% ,4    " #D.8)9'#AEZC\!   \ @  #P              @ %>$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ Y#F"620>FZ*M    ^ $  !H
M             ( !RA$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ Y#F"6660>9(9 0  SP,  !,              ( !KQ(  %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  ^1,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tmb-20241127x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tmb-20241127.xsd</File>
    <File>tmb-20241127_def.xml</File>
    <File>tmb-20241127_lab.xml</File>
    <File>tmb-20241127_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="tmb-20241127x8k.htm">tmb-20241127x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tmb-20241127x8k.htm": {
   "nsprefix": "ptct",
   "nsuri": "http://www.ptcbio.com/20241127",
   "dts": {
    "schema": {
     "local": [
      "tmb-20241127.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "tmb-20241127_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "tmb-20241127_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tmb-20241127_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "tmb-20241127x8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20241127x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tmb-20241127x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ptcbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001070081-24-000029-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001070081-24-000029-xbrl.zip
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MM"C30"TPM.1V@6Y545"))J U%P)=:,[F@% <A:=A%/9[".-AA7%!C1NC)*K
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ME;^&$-(Y.=',L3;[3 F?N/P&?U<?B4E#-UR;[;X/1H(MN1?501C#TCS7(TQ
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M&S>2?P6K[,Q8;WGKL$0Z>BM+2FS'EK62,I[9+_O ;I"-J+O1 Z!)T;]^JPI
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MER"T(I5E0D<P*U"/*53NI0?":@+25<WQ27BJ2 4)635A1<HC,5;M"!:CX1F
M=J%TN*ORJ<)WSE[__?UE^]4Q[+.,%]\\C)'V"+R),A:T$6Q^ H0&C@]('[@,
MFS\648<-6@S-R!:*HSTPMQG/V,G%99O=__[O0-7<HV[Y/>;N8)W1..;1U52K
M,H^'/TSHOU7<XWOLKJW?#X?GYR>G+7;:>=-I+>&83(5_&^ ;!\Q15=/D:;'7
M.4SP[/3PXOCP?X9X_W(3&#6';:.+;57,%R3O#)  LAEP'$>9%J6E0?W@V3YM
M6$G1DI7$;["2SD"J9L#8N Z>&K"M=.'? 6)FIAP;&4L.N@6FK-XZ_!D6^\^+
MDR$[_?O%9HML+93*:^RMK7VPMF)O;17.VFJQ.?A4"0AQ6'\,]$%&.FPT4ZF(
M2A#.'?8K>(.:]EPMO56S8]"+ (2RF&C$1L$7M#]89R!+SG*> 8;^[W5N_V_W
MXO27G?>+C^BE\5MA$ T0!AR1 I#"5+<8KM70[F'8WZOD$5=.-7H]V="/+7IC
M23-Z;;E60=+0G3NS&N_')@8)]*]2V9$G."!)W"UX@S%QAT85Z&BNG:E83A9X
MV1+++59@2\1[(\62;0%#"Y#\*D/W!.C+)C!AS5$([PAUJ+$5@^$[@) ,AJG>
ML!CF(G2ZQ0.H9<S><0L/S]G+#OLE%1+8[EWG&)!VE$@Q82?7P!#HO[+WDPEP
MMVY](CTZS UWB7,L<SUH\+%$&Q#>J5P?<5T(Y&+1  2"QV2HT0(+,E. -*G!
MAE2R)#K6C_>I_;%B<,B//-@,N2BU,I$D=5K-TF$?!($4I)NT)/T:NQ(K\@M]
MQ"@2J:![!'6%6$#3!J;P]($HQGL)J!$@?(]$50*%N2]@L!2P+G@1=JET&L]E
M3/O)!<8E0=I6U /R"H2P6]<8EB/2M&V56T!,FT7)/)F(B-!V(QEV:FE6&A$(
M)A+5\HAB@ 7 <D. P70 :1Q?E;K&#IAE%K:7@0%(:\&_:"V7!5IG34N/I$ #
M+W@?C#V)$(2EDO77<:3TR+G_C_%_[TV2P3H'O=%G@A0H;1!UW%B.SX#"Y6"M
MX1^84];"KL,NET43,8OW*R48CJ!4'>&J%(25)E):8L-"%@)W3M2BQ02$ ; $
M49Q%"I_*"+@I*DW%UI)$FB?/5 'CYB#-\&[%B>G"43+2*07C&"^ UGF4"!>G
MH27$8BIR9*,&VWB9DP 66)EGX+LA0YH6P:SO).BM5? G&&%_!R8ZY9H;F24<
M)/+1R?NF_=.YARD]%8#L2Y6Z0JC,N7:X*F7JU%I.B%B2MY^!'** GG68A8=!
MRE7*B:@A"!8>S[@3PD GM0"=2 U>#T9:4G OG5H-8C"(5!@3J:#,@?<Z'BV/
MG.6^+_'A5=R<D]$2J1F9=F 39T[KDSDS \4;DX):HSB 3M!R*#4XMA9X=2S(
M'  '7L(+WI*L'/P$)=*@=O0M+K@#'@S($YEA/*%,+9KTJ%_<^V]*$"B4TXM%
M!H:2=;K2)N M^^57MI$?P+T8EYJ#U=H"ZQ54:"P*%&#T3%PZK0@/C8%AG.(%
M\TB,09:!.8/4FY9@7CT[NOAIDV6EY?!>D+'P%L@?"_MDSUY=@J^5HEXT31TJ
MN 90H*I'MPB8?V4)8^ X-+=A#5=B 1PB<_2@6 ;,5VJ2O@:C ?T!F%2Y36JA
M :KYEIC'Y-D,90!,Z,,"5A5 "_T771C]3N72U^=?FDQ%"<?E!.-C2!VY?Q,=
M7JZ#"VTP,94>_M"C_T:-C2W?\(M:#57TUNV_F0/U.=NE'.CRM2I/6_"I:(^!
M'Z[:? ),->3IG"^,!^?SW<[V\[^,P!@&_]AGO'J?9'X?)J/\B#/(>X/M5:C\
M&3/(:T-J7\@@WX7PZ*W+]2VS2 .A2% [#Z&&O_DD]'T9$:\SU-8<U7\KJ&0,
M],N\%.1/-A0W^"(3/E.DF<$ GPCK8E+."780=,&H5'P'2N\1XNM[,F#GB;2B
M;0H>B6&A17L.XA+&7YO<6LI5+1H9_LIC_NJ\EP]#M1KI+K1REU->SNYM.\/W
M\_FO8 Y7H6T7%XM\ $M%8%Z3"]9'0WBGPYYH["'EVZ7'+<]='!-HRL7)*>0=
MDLI((JDR!N/IF#-AV[WN;H^-N0%T/MON_85"*?C4+GP.)+KYV(/EWR$J?<6'
MY]%FF!0P9<KQ;\!Y%#@N#>P9TU?A%6#?F)0RX-CEG_!J([U"ZARC(1A,$ZQ
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MS,%A8A\2X>[0(J2I5PA6N6VL"KRP<8YIXY0] U&(>1QPJ3?797+(+*>2D&M
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MR"H[(8H[\T1U0/UWQUK-C>CWNVD[ZXK\ARX^A,_4C\#C78QEVD5WT-\:]/=
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M8BTR,#(T,3$R-U]D968N>&UL4$L! A0#%     @ Y#F"63]$XY>R!0  HT
M !0              ( !#P<  '1M8BTR,#(T,3$R-U]L86(N>&UL4$L! A0#
M%     @ Y#F"60=8=(!Q!   MR4  !0              ( !\PP  '1M8BTR
M,#(T,3$R-U]P<F4N>&UL4$L! A0#%     @ Y#F"6<LY-8OL'P  FLT  !,
M             ( !EA$  '1M8BTR,#(T,3$R-W@X:RYH=&U02P$"% ,4
M" #D.8)9CMBO.?09  "%C@  %P              @ &S,0  =&UB+3(P,C0Q
D,3(W>&5X.3ED,2YH=&U02P4&      8 !@"* 0  W$L

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>tmb-20241127x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tmb-20241127.xsd" xlink:type="simple"/>
    <context id="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070081</identifier>
        </entity>
        <period>
            <startDate>2024-11-27</startDate>
            <endDate>2024-11-27</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_Kny3NXcbFES9jY3A4LBEDg_2_1">0001070081</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_W7Vshdy70UmEuivjp3k60g_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_bLsj63tgK0OUDo06i7jgLQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_ojaMruoDVkeM-HseBB0_Ww">2024-11-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_L83Du03NWkG9t_03uHFNPg">PTC THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_eJjXzFK03keuopRPMANf5Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_SfD8PALNZUGB-KScF4Q01A_1_2">001-35969</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_DdcXfBP45kuYrcH0A1gkQQ_1_4">04-3416587</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_HTo0rO1LnUKD7-vZEy5QzA_1_0">500 Warren Corporate Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_zDcVq8wmSkWr-mUCU3jx8Q">Warren</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_jXOixc14Ekq-1GfIN8QmrA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_Ll-ydGgm_021sgPkoJdWKQ_2_3">07059</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_4vITLWlpNEmoGNW-KuuSjg">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_NVf5i4P11UusXEndMIx8tw">222-7000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_yPEfOoj3BEW9chCShzV3cw">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_NxYJmQ5jekGrT6LMVzRsbQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_KrWwJjTLeE-NcU0dKU2neA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_gSIkmnKoOEm0KSD-fct3Ww">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_fhm4NPmuHkmCBPHYqWfkNg_2_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_th9KmC7r10C35sAYmKYYOQ_2_2">PTCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Tc_RI2JeI5-6kCsTi21Qdh0yg_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_11_27_2024_To_11_27_2024_8Dd7ar6BBEG4il6zDyU7XQ"
      id="Narr_hznf45cJHEOdeSdAiodnZQ">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
